سعر بتنوفيت Betnovate‏ محلول لفروة الرأس 30 مل 0.1% 2026

Betnovate 0.1 % Scalp Application 30 Ml (30 mL bottle), topical corticosteroid (Betamethasone) marketed in Egypt by Glaxo Smithkline.

• Common: pruritus, local skin burning/pain. Very rare: skin atrophy and thinning, striae, telangiectasia, pigmentation changes, hypertrichosis, allergic contact dermatitis, HPA-axis suppression and Cushingoid features; withdrawal reactions (not known).International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Hypersensitivity; infections of the scalp; dermatoses in children under one year of age.International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Increased systemic absorption can cause Cushing's syndrome and reversible HPA-axis suppression; risk rises with potency, duration, large areas, occlusion (including nappies), thin or broken skin and in children. Withdraw gradually; abrupt withdrawal may cause glucocorticoid insufficiency or rebound.International label, same formulation · MHRA / electronic Medicines Compendium (eMC)
• Flammable: keep away from fire, flames and smoking during and immediately after use.International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

• Limited human data; topical corticosteroids caused fetal abnormalities in animals. Use in pregnancy only if benefit outweighs risk, in the minimum quantity for the minimum duration.International label, same formulation · MHRA / electronic Medicines Compendium (eMC)
• Safe use in lactation not established; use only if benefit outweighs risk and do not apply to the breasts.International label, same formulation · MHRA / electronic Medicines Compendium (eMC)

English text not available for this section.